BTIG Research restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $16.00 price objective on the stock.
Several other equities analysts have also weighed in on COYA. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Friday, July 17th. Roth Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Coya Therapeutics in a report on Monday, August 24th. HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a research report on Monday, August 24th. Finally, Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.33.
Read Our Latest Analysis on Coya Therapeutics
Coya Therapeutics Stock Performance
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. Sell-side analysts forecast that Coya Therapeutics will post -1.34 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Allworth Financial LP grew its holdings in Coya Therapeutics by 1,200.0% during the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after purchasing an additional 12,000 shares in the last quarter. AXQ Capital LP purchased a new stake in Coya Therapeutics during the 2nd quarter worth $116,000. Cetera Investment Advisers increased its stake in Coya Therapeutics by 36.4% during the 1st quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock worth $118,000 after buying an additional 8,000 shares during the period. ADAR1 Capital Management LLC acquired a new position in Coya Therapeutics in the 1st quarter worth $161,000. Finally, Long Corridor Asset Management Ltd purchased a new position in Coya Therapeutics in the 4th quarter valued at about $225,000. 39.75% of the stock is owned by institutional investors and hedge funds.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies designed to enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune responses and may play a role in limiting inflammation associated with neurodegenerative and autoimmune diseases.
The company’s pipeline includes investigational Treg-based therapies, including COYA 301, an autologous Treg therapy being evaluated for potential use in conditions such as amyotrophic lateral sclerosis (ALS).
Featured Stories
- Five stocks we like better than Coya Therapeutics
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
